JP2022523074A5 - - Google Patents

Info

Publication number
JP2022523074A5
JP2022523074A5 JP2021544152A JP2021544152A JP2022523074A5 JP 2022523074 A5 JP2022523074 A5 JP 2022523074A5 JP 2021544152 A JP2021544152 A JP 2021544152A JP 2021544152 A JP2021544152 A JP 2021544152A JP 2022523074 A5 JP2022523074 A5 JP 2022523074A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
melanoma
cell carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021544152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523074A (ja
JP7665518B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015723 external-priority patent/WO2020160180A1/en
Publication of JP2022523074A publication Critical patent/JP2022523074A/ja
Publication of JP2022523074A5 publication Critical patent/JP2022523074A5/ja
Application granted granted Critical
Publication of JP7665518B2 publication Critical patent/JP7665518B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021544152A 2019-01-29 2020-01-29 化合物及びその使用 Active JP7665518B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962798406P 2019-01-29 2019-01-29
US62/798,406 2019-01-29
US201962881275P 2019-07-31 2019-07-31
US62/881,275 2019-07-31
US201962938415P 2019-11-21 2019-11-21
US62/938,415 2019-11-21
PCT/US2020/015723 WO2020160180A1 (en) 2019-01-29 2020-01-29 Compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2022523074A JP2022523074A (ja) 2022-04-21
JP2022523074A5 true JP2022523074A5 (cg-RX-API-DMAC7.html) 2023-02-07
JP7665518B2 JP7665518B2 (ja) 2025-04-21

Family

ID=71841237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544152A Active JP7665518B2 (ja) 2019-01-29 2020-01-29 化合物及びその使用

Country Status (8)

Country Link
US (1) US20230079819A1 (cg-RX-API-DMAC7.html)
EP (1) EP3917527B1 (cg-RX-API-DMAC7.html)
JP (1) JP7665518B2 (cg-RX-API-DMAC7.html)
CN (1) CN113645971B (cg-RX-API-DMAC7.html)
AU (1) AU2020214308A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032327T3 (cg-RX-API-DMAC7.html)
IL (1) IL285177B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020160180A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
WO2021155262A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
BR112022015109A2 (pt) * 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
WO2021236080A1 (en) * 2020-05-20 2021-11-25 Foghorn Therapeutics Inc. Methods of treating cancers
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US20240132485A1 (en) * 2020-10-16 2024-04-25 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
WO2022198043A1 (en) * 2021-03-19 2022-09-22 Foghorn Therapeutics Inc. Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm
US20250339441A1 (en) * 2022-04-08 2025-11-06 Foghorn Therapeutics Inc. Methods of treating cancer
AU2023278401A1 (en) * 2022-06-02 2025-01-23 Shanghai Shijiang Biotechnology Co., Ltd Phosphorus compound and use thereof
CN119768400A (zh) * 2022-11-11 2025-04-04 苏州信诺维医药科技股份有限公司 一种稠环化合物、其用途及含其的药物组合物
WO2025082531A1 (en) * 2023-10-20 2025-04-24 Suzhou Zanrong Pharma Limited Compounds and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005261487A1 (en) 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
US9656959B2 (en) 2010-12-22 2017-05-23 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
MX2016012007A (es) * 2014-03-18 2016-12-05 Hoffmann La Roche Compuestos de oxepan-2-il-pirazol-4-il-heterociclil-carboxamida y metodos de uso.
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2018187614A1 (en) * 2017-04-05 2018-10-11 Foghorn Therapeutics Compounds and uses thereof
WO2018213422A1 (en) * 2017-05-17 2018-11-22 Foghorn Therapeutics Compounds and uses thereof
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
EP3883580A4 (en) 2018-11-21 2023-01-04 Foghorn Therapeutics Inc. Methods of treating cancers
MX2021006421A (es) 2018-12-19 2021-08-16 Leo Pharma As Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
EA202192101A1 (ru) * 2019-11-21 2021-12-09 Фогхорн Терапьютикс Инк. Соединения и их применение
IL295176A (en) * 2020-01-29 2022-09-01 Foghorn Therapeutics Inc compounds and their uses

Similar Documents

Publication Publication Date Title
Petroni et al. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
JP2024529976A5 (cg-RX-API-DMAC7.html)
JP2023512038A5 (cg-RX-API-DMAC7.html)
JP6706255B2 (ja) 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
JP2020158507A6 (ja) 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
JP2011144190A (ja) 抗癌剤の効果増強剤
CN117919235A (zh) 一种萘酰胺化合物治疗kras突变相关疾病的用途
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
JP2023512039A5 (cg-RX-API-DMAC7.html)
Kelly et al. Chemotherapy in metastatic colorectal cancer
Ke-Chun et al. The role of SPDEF in cancer: promoter or suppressor.
Malaponte et al. Detection of BRAF gene mutation in primary choroidal melanoma tissue
CN108434455A (zh) Mthfd2特异性抑制剂在防治结直肠癌方面的应用
US11389536B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
ES2239928T3 (es) Metodo para reducir el dolor utilizando virus oncoliticos.
CN112566628A (zh) 预防和治疗癌症的药物组合物,包括棉酚、苯乙双胍和抗癌剂
Vieito et al. 614MO Type II RAF inhibitor tovorafenib in recurrent/refractory (R/R) melanoma or other solid tumors with RAF fusions and/or RAF1 amplification
CN115429883A (zh) 用于联合治疗的抗肿瘤药物组合物
ES3030540T3 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
ES2389809T3 (es) Terapias anticancerosas
Irusta Roads to the strategic targeting of ovarian cancer treatment
IL307965A (en) compounds and their uses
EP4725489A2 (en) Treatment of canine cancers
CN115397422A (zh) 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途
JP2026516286A (ja) マイクロペプチドmiacの使用